These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2502913)

  • 1. Fibrinogenolysis in thrombotic thrombocytopenic purpura.
    Kakishita E; Koyama T; Higuchi M; Kunitomi O; Oura Y; Nagai K
    Am J Hematol; 1989 Sep; 32(1):14-9. PubMed ID: 2502913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
    Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
    Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
    Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
    Wada H; Kaneko T; Ohiwa M; Tanigawa M; Hayashi T; Tamaki S; Minami N; Deguchi K; Suzuki K; Nakano T
    Am J Hematol; 1993 Oct; 44(2):101-5. PubMed ID: 8266913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
    Fukao H; Yamamoto K; Matsuo O
    Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
    Sakata Y; Murakami T; Noro A; Mori K; Matsuda M
    Blood; 1991 May; 77(9):1949-57. PubMed ID: 1708294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.
    Glas-Greenwalt P; Hall JM; Panke TW; Kant KS; Allen CM; Pollak VE
    J Lab Clin Med; 1986 Nov; 108(5):415-22. PubMed ID: 2430036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ; Páramo JA; Rocha E
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor activity in bacterial infection.
    Páramo JA; Fernández Diaz FJ; Rocha E
    Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
    Xu Y; Hagege J; Mougenot B; Sraer JD; Rønne E; Rondeau E
    Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
    Velasco F; Torres A; Rojas R; Alvarez MA; Gomez P; Castillo D
    Haemostasis; 1992; 22(3):117-23. PubMed ID: 1427455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
    Falkon L; Garí M; Borrell M; Fontcuberta J
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.
    Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
    Am J Hematol; 1991 Mar; 36(3):176-83. PubMed ID: 1899963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
    Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
    Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.
    Asakura H; Ontachi Y; Mizutani T; Kato M; Saito M; Kumabashiri I; Morishita E; Yamazaki M; Aoshima K; Nakao S
    Crit Care Med; 2001 Jun; 29(6):1164-8. PubMed ID: 11395595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in molecular markers in patients with thrombotic thrombocytopenic purpura].
    Takamatsu J
    Nihon Rinsho; 1993 Jan; 51(1):135-7. PubMed ID: 8433505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of proteases type plasminogen activator and their inhibitor in cornea.
    Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
    Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura.
    Sakai K; Wada H; Nakatsuka Y; Kubo M; Hayakawa M; Matsumoto M
    J Intensive Care Med; 2021 Apr; 36(4):436-442. PubMed ID: 31964209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.